Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 5/20 | 0.57 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | GSK3A | P49840 | 2/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 1/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14003429 | 1.00 | HINT1 (0.57) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL12740468 | 0.91 | HINT1 (0.55) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL19884479 | 0.91 | HINT1 (0.66) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL16375317 | 0.90 | HINT1 (0.55) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL26268365 | 0.90 | HINT1 (0.55) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL19035716 | 0.90 | HPGD (0.61) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL25605693 | 0.88 | HINT1 (0.55) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL19035717 | 0.88 | HINT1 (0.52) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL14929063 | 0.87 | HINT1 (0.54) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL14946245 | 0.87 | HINT1 (0.54) | HINT1NT5EHPGDGSK3ARPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501504-B2 | Detectable labeled nucleoside analogs and methods of use thereof | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7456266-B2 | Detectable labeled nucleoside analogs and methods of use thereof | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070208169-A1 | DETECTABLE LABELED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070202576-A1 | DETECTABLE LABELED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070202576-A1 | DETECTABLE LABELED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF | SAMHD1, NUDT1, DUT | HINT1 287/4885NT5E 27/4885HPGD 1036/4885 |
| US-20070208169-A1 | DETECTABLE LABELED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF | SAMHD1, NUDT1, DUT | HINT1 287/4885NT5E 27/4885HPGD 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.